11/01/2017 21:27:11

SHAREHOLDER COMPLAINT: Levi & Korsinsky, LLP Files in U.S. District Court to Recover Losses Suffered by Investors in Ophthotech Corporation – Sets Lead Plaintiff Deadline of March 13, 2017

Related content
12:50 - 
Report: Exploring Fundamental Drivers Behind Carter's, ..
08 Mar - 
INVESTOR COMPLAINT: Levi & Korsinsky, LLP Reminds Inves..
07 Mar - 
DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Rem..

NEW YORK, Jan. 11, 2017 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired shares of Ophthotech Corporation (“Ophthotech”) (NASDAQ:OPHT) between May 11, 2015 and December 12, 2016. You are hereby notified that Levi & Korsinsky has commenced the class action Micholle v. Ophthotech Corporation, et al.(Case No. 1:17-cv-00210) in the USDC for the Southern District of New York. To get more information go to:

http://zlk.9nl.com/ophthotech

or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The complaint alleges that, throughout the Class Period, Ophthotech made overtly positive representations about the effectiveness and potential of its treatment Fovista when used in combination with Lucentis, a commercially available anti-vascular endothelial growth factor agent, despite awareness that the phase 3 clinical trial of Fovista would fail to achieve its primary endpoint of change in best corrected visual acuity from baseline at 12 months over Lucentis alone. The complaint further alleges that these statements caused Ophthotech stock to trade at artificially inflated prices.

On December 12, 2016, Ophthotech announced that the trial had failed to achieve its primary endpoint, and that Fovista and Lucentis demonstrated a non-statically significant improvement over patients only receiving Lucentis. Following this news, shares of Ophthotech fell approximately 86% to close at $5.29.

Take Action: if you suffered a loss in Ophthotech you have until March 13, 2017to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

30 Broad Street - 24th Floor

New York, NY 10004

Tel: (212) 363-7500

Toll Free: (877) 363-5972

Fax: (212) 363-7171

www.zlk.com

Primary Logo

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

Regulatory news

Majedie Asset Management Ltd : Form 8.3 - TESCO PLC

21/11/2017 15:35:27
FORM 8.3   PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code")   1.         KEY INFORMATION   (a) Full name of discloser: ..

Alliance Trust PLC : Net Asset Value(s)

21/11/2017 13:37:22
ALLIANCE TRUST PLC                                    At the close of business on Monday 20 November 2017: The Company's NAV per ordinary share, valued on a bid price basis with Debt at Par, was -       excluding income, 778.0p -       including income, 787.7p  The Company's NAV per ordinary share, valued on a bid price basis with Debt at Fair Value, was -       excluding inc..

Admiral Group PLC : Holding(s) in Company

21/11/2017 10:20:10
TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i   1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii : ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Genmab Announces European Regulatory Submission for Daratumumab in Front Line Multiple Myeloma
2
Novea Inc.'s Captive Insurance Subsidiary Jacana Insurance Engages Madison RE I.I. to Provide Reinsurance for Jacana Warranty Offerings
3
ICTV Brands Reports 3Q17 Financial Results
4
Aryaka to Present Global SD-WAN Use Cases and Enterprise Deployment Stories at 6th Annual CIO Leaders Singapore Summit
5
Zomedica Pharmaceuticals Corp. Registration Statement Declared Effective by U.S. Securities and Exchange Commission

Related stock quotes

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2017   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
21 November 2017 21:10:12
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20171108.1 - EUROWEB3 - 2017-11-21 22:10:12 - 2017-11-21 21:10:12 - 1000 - Website: OKAY